Cargando…

A Causal Treatment for X-Linked Hypohidrotic Ectodermal Dysplasia: Long-Term Results of Short-Term Perinatal Ectodysplasin A1 Replacement

X-linked hypohidrotic ectodermal dysplasia (XLHED), caused by a genetic deficiency of ectodysplasin A1 (EDA1), is a rare developmental disorder of ectodermal derivatives such as hair, sweat glands, and teeth. The absence of sweat glands and perspiration can evoke life-threatening hyperthermia. As mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneider, Holm, Schweikl, Christine, Faschingbauer, Florian, Hadj-Rabia, Smail, Schneider, Pascal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138843/
https://www.ncbi.nlm.nih.gov/pubmed/37108325
http://dx.doi.org/10.3390/ijms24087155
_version_ 1785032802947825664
author Schneider, Holm
Schweikl, Christine
Faschingbauer, Florian
Hadj-Rabia, Smail
Schneider, Pascal
author_facet Schneider, Holm
Schweikl, Christine
Faschingbauer, Florian
Hadj-Rabia, Smail
Schneider, Pascal
author_sort Schneider, Holm
collection PubMed
description X-linked hypohidrotic ectodermal dysplasia (XLHED), caused by a genetic deficiency of ectodysplasin A1 (EDA1), is a rare developmental disorder of ectodermal derivatives such as hair, sweat glands, and teeth. The absence of sweat glands and perspiration can evoke life-threatening hyperthermia. As molecular genetic findings are not always conclusive, the concentrations of circulating EDA1 may help to distinguish between total and partial EDA1 deficiencies. We previously treated nine male patients with obvious signs of XLHED with a recombinant EDA1 replacement protein, Fc-EDA, either shortly after birth (n = 3) or by prenatal administration in gestational week 26 and beyond (n = 6). Here, we present the long-term follow-up for up to six years. In patients who had received Fc-EDA after birth, neither sweat glands nor sweating ability were detected at the age of 12–60 months. In contrast, prenatal EDA1 replacement resulted in ample sweat gland development and pilocarpine-inducible sweating in all treated subjects, who also attained more permanent teeth than their untreated affected relatives. Normal perspiration has persisted for six years in the two oldest boys treated repeatedly with Fc-EDA in utero. When they had a sauna, adequate thermoregulation was evidenced. Lower sweat production after single prenatal dosing may indicate a dose–response relationship. The absence of circulating EDA1 in five prenatally treated subjects proved that these children would have been unable to perspire if they had been left untreated. The sixth infant was shown to produce an EDA1 molecule that, albeit interacting with its cognate receptor, cannot activate EDA1 signaling. In conclusion, a causal treatment of XLHED before birth is feasible.
format Online
Article
Text
id pubmed-10138843
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101388432023-04-28 A Causal Treatment for X-Linked Hypohidrotic Ectodermal Dysplasia: Long-Term Results of Short-Term Perinatal Ectodysplasin A1 Replacement Schneider, Holm Schweikl, Christine Faschingbauer, Florian Hadj-Rabia, Smail Schneider, Pascal Int J Mol Sci Article X-linked hypohidrotic ectodermal dysplasia (XLHED), caused by a genetic deficiency of ectodysplasin A1 (EDA1), is a rare developmental disorder of ectodermal derivatives such as hair, sweat glands, and teeth. The absence of sweat glands and perspiration can evoke life-threatening hyperthermia. As molecular genetic findings are not always conclusive, the concentrations of circulating EDA1 may help to distinguish between total and partial EDA1 deficiencies. We previously treated nine male patients with obvious signs of XLHED with a recombinant EDA1 replacement protein, Fc-EDA, either shortly after birth (n = 3) or by prenatal administration in gestational week 26 and beyond (n = 6). Here, we present the long-term follow-up for up to six years. In patients who had received Fc-EDA after birth, neither sweat glands nor sweating ability were detected at the age of 12–60 months. In contrast, prenatal EDA1 replacement resulted in ample sweat gland development and pilocarpine-inducible sweating in all treated subjects, who also attained more permanent teeth than their untreated affected relatives. Normal perspiration has persisted for six years in the two oldest boys treated repeatedly with Fc-EDA in utero. When they had a sauna, adequate thermoregulation was evidenced. Lower sweat production after single prenatal dosing may indicate a dose–response relationship. The absence of circulating EDA1 in five prenatally treated subjects proved that these children would have been unable to perspire if they had been left untreated. The sixth infant was shown to produce an EDA1 molecule that, albeit interacting with its cognate receptor, cannot activate EDA1 signaling. In conclusion, a causal treatment of XLHED before birth is feasible. MDPI 2023-04-12 /pmc/articles/PMC10138843/ /pubmed/37108325 http://dx.doi.org/10.3390/ijms24087155 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Schneider, Holm
Schweikl, Christine
Faschingbauer, Florian
Hadj-Rabia, Smail
Schneider, Pascal
A Causal Treatment for X-Linked Hypohidrotic Ectodermal Dysplasia: Long-Term Results of Short-Term Perinatal Ectodysplasin A1 Replacement
title A Causal Treatment for X-Linked Hypohidrotic Ectodermal Dysplasia: Long-Term Results of Short-Term Perinatal Ectodysplasin A1 Replacement
title_full A Causal Treatment for X-Linked Hypohidrotic Ectodermal Dysplasia: Long-Term Results of Short-Term Perinatal Ectodysplasin A1 Replacement
title_fullStr A Causal Treatment for X-Linked Hypohidrotic Ectodermal Dysplasia: Long-Term Results of Short-Term Perinatal Ectodysplasin A1 Replacement
title_full_unstemmed A Causal Treatment for X-Linked Hypohidrotic Ectodermal Dysplasia: Long-Term Results of Short-Term Perinatal Ectodysplasin A1 Replacement
title_short A Causal Treatment for X-Linked Hypohidrotic Ectodermal Dysplasia: Long-Term Results of Short-Term Perinatal Ectodysplasin A1 Replacement
title_sort causal treatment for x-linked hypohidrotic ectodermal dysplasia: long-term results of short-term perinatal ectodysplasin a1 replacement
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138843/
https://www.ncbi.nlm.nih.gov/pubmed/37108325
http://dx.doi.org/10.3390/ijms24087155
work_keys_str_mv AT schneiderholm acausaltreatmentforxlinkedhypohidroticectodermaldysplasialongtermresultsofshorttermperinatalectodysplasina1replacement
AT schweiklchristine acausaltreatmentforxlinkedhypohidroticectodermaldysplasialongtermresultsofshorttermperinatalectodysplasina1replacement
AT faschingbauerflorian acausaltreatmentforxlinkedhypohidroticectodermaldysplasialongtermresultsofshorttermperinatalectodysplasina1replacement
AT hadjrabiasmail acausaltreatmentforxlinkedhypohidroticectodermaldysplasialongtermresultsofshorttermperinatalectodysplasina1replacement
AT schneiderpascal acausaltreatmentforxlinkedhypohidroticectodermaldysplasialongtermresultsofshorttermperinatalectodysplasina1replacement
AT schneiderholm causaltreatmentforxlinkedhypohidroticectodermaldysplasialongtermresultsofshorttermperinatalectodysplasina1replacement
AT schweiklchristine causaltreatmentforxlinkedhypohidroticectodermaldysplasialongtermresultsofshorttermperinatalectodysplasina1replacement
AT faschingbauerflorian causaltreatmentforxlinkedhypohidroticectodermaldysplasialongtermresultsofshorttermperinatalectodysplasina1replacement
AT hadjrabiasmail causaltreatmentforxlinkedhypohidroticectodermaldysplasialongtermresultsofshorttermperinatalectodysplasina1replacement
AT schneiderpascal causaltreatmentforxlinkedhypohidroticectodermaldysplasialongtermresultsofshorttermperinatalectodysplasina1replacement